319 results on '"de Braud F"'
Search Results
2. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
3. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
4. P2.10-11 Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer
5. OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
6. PB0709 Thrombin Generation (TG) and D-Dimer Significantly Predict Early-Disease Recurrence (E-DR) in High-Risk Breast Cancer
7. EE560 The Impact of Molecular Tumour Board on Costs and Patient Access to Personalized Medicine
8. PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers
9. P1.15-02 Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
10. MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)
11. PO-04: Thrombin generation and D-dimer significantly predict for early disease progression and mortality in patients with gastrointestinal cancer
12. PO-49: Genomic determinants and clinical relevance of cancer- associated thrombosis in biliary tract cancers
13. Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA
14. Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors
15. Mammographic density to predict response to neoadjuvant systemic breast cancer therapy
16. Efficacité et sécurité du selpercatinib (LOXO-292) par dernier traitement systémique reçu chez les patients (pts) atteints de cancer bronchique non à petites cellules (CBNPC) ayant une fusion du gène RET (RET+)
17. Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
18. 654MO A phase II prospective trial of frontline cabozantinib in metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2)
19. 1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
20. 1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma
21. 383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)
22. 1647TiP Antiandrogen therapy and TMPRSS2 status: How prostate cancer patients are protected from COVID-19 pandemic
23. Skip pattern approach toward the early access of innovative anticancer drugs
24. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population
25. PO-83 Assessment model for thrombotic risk in a prospective cohort of newly diagnosed metastatic cancer outpatient candidates for chemotherapy
26. Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy”
27. PO-85 Finding a risk assessment model for thromboembolic events in hospitalized cancer patients: the INDICATE study
28. 7O Updated results from phase I study of CC-90011 in patients (pts) with solid tumours (STs), including neuroendocrine neoplasms (NENs), and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)
29. 17P BCL6 and Notch pathway: A signaling axis leading to a novel druggable biotarget in triple-negative breast cancer
30. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort
31. Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy
32. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial
33. Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC)
34. 79TiP A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer
35. 175P Prognostic role of body mass index (BMI) in patients with Human Epidermal growth factor Receptor 2 (HER2)–positive early breast cancer treated with adjuvant trastuzumab-containing chemotherapy
36. 1312P Chemotherapy followed by immunotherapy compared to reverse sequence in NSCLC with PD-L1 low expression: PFS2 analysis
37. 339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study
38. 528O CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
39. 1290P Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC)
40. 65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts
41. 364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
42. 749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
43. 540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy
44. 1089P POD1UM-201: A phase II study of retifanlimab (INCMGA00012) in advanced or metastatic Merkel cell carcinoma (MCC)
45. 1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis
46. O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
47. O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma
48. 18O CC-90011 in patients (Pts) with advanced solid tumors (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study
49. Anticancer innovative therapy: Highlights from the ninth annual meeting
50. Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.